I am a
Home I AM A Search Login

Papers of the Week


January 27, 2023


Eur J Neurol


http://www.ncbi.nlm.nih.gov/pubmed/36583633?dopt=Abstract

Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.

Authors

Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen C L, Josiassen M K, Phul R, Sperling B
Eur J Neurol. 2022 Dec 30.
PMID: 36583633.

Abstract

In the phase 3b, randomized, double-blind, placebo-controlled DELIVER clinical trial, eptinezumab reduced migraine frequency and headache in adults with two to four prior preventive treatment failures. Here the effect of eptinezumab on coinciding patient-reported outcomes is reported.